EMA’s CHMP Begins Review of SK Chemicals’ Skycovion COVID-19 Vaccine

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) is reviewing a marketing authorization application by South Korea-based SK Chemicals for its Skycovion COVID-19 vaccine.

Unlike the messenger RNA vaccines from Pfizer-BioNTech and Moderna, Skycovion is an adjuvanted vaccine with nanoparticles of the SARS-CoV-2 spike protein.

The company has submitted data to the EMA’s expert panel showing the vaccine’s safety and efficacy in triggering the production of antibodies against the original strain of SARS-CoV-2.

The EMA said that it is “important that the EU has a wide array of vaccines and treatments” as the pandemic continues to evolve.